# QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

> **NCT05799820** · PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** QL1706
- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin injection
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05799820
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-29
- **Primary completion:** 2024-03-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05799820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05799820, "QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05799820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*